See also this year's filing and all EDGAR filings for this company.
PDF Report 0001743881_2022_Bridgebio_Pharma_Inc.pdf
Logs
| warning | Large missing amount for aggregate "Liabilities" added to remainder. | industry.us_generic | {'missing_ratio': 2.103114396069504, 'aggregate_val': 1878371000, 'exp_sum': 605318000, 'exp_to_value': {'LiabilitiesCurrent': 135069000, 'LiabilitiesNoncurrent': 470249000, 'remainder_Liabilities': 0}} |
| warning | Large missing amount for aggregate "Liabilities" added to remainder. | industry.us_generic | {'missing_ratio': 2.1588702231211254, 'aggregate_val': 1867960000, 'exp_sum': 591338000, 'exp_to_value': {'LiabilitiesCurrent': 121428000, 'LiabilitiesNoncurrent': 469910000, 'remainder_Liabilities': 0}} |
Graph
Absolute values for 0001743881, Bridgebio Pharma Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 888,858,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 44,934,000 |
| 2 | PropertyPlantAndEquipmentNet | 30,066,000 |
| 3 | remainder_Assets | 48,934,000 |
| 4 | LiabilitiesCurrent | 135,069,000 |
| 5 | LiabilitiesNoncurrent | 470,249,000 |
| 6 | remainder_Liabilities | 1,273,053,000 |
| 7 | CostOfGoodsAndServicesSold | 2,735,000 |
| 8 | SellingGeneralAndAdministrativeExpense | 192,210,000 |
| 9 | ResearchAndDevelopmentExpense | 451,024,000 |
| 10 | remainder_Expenses | 379,000 |
| 11 | remainder_Revenues | 69,716,000 |
| 12 | remainder_NetIncome | -9,822,000 |
| 13 | remainder_ComprehensiveNetIncome | 23,591,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 1,012,792,000 |
| 1 | Liabilities | 1,878,371,000 |
| 2 | Expenses | 646,348,000 |
| 3 | Revenues | 69,716,000 |
| 4 | StockholdersEquity | -865,579,000 |
| 5 | NetIncome | -586,454,000 |
| 6 | ComprehensiveNetIncome | -574,658,500 |
| 7 | BaseVar | 1,820,320,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | -1.70 |
| 9 | EconomicCapitalRatio | 1.12 |
Edgar->Model Mapping
Feature Distribution
Change over Time
